I don't own stock in HMPR but do plan to keep this bank

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt

I don't own stock in HMPR but do plan to keep this bank on my radar. Based in Virginia, this bank has assets of over 1.7 billion dollars which makes it a bit bigger than the banks I usually follow. Over the last year The Bank of Hampton Roads has made some good strides in returning to profitability. One massive thing in their favor is that not one cent of TARP money was ever taken. The pps is at 1.31 as of this post but don't expect it to remain there. I think HMPR will be a solid 2.00 + stock by the end of 2013.

VectorVest Logo
Hampton Roads (HMPR)
$1.31
0.02 (1.55%)
Thursday, March 28, 2013
HMPR is fairly valued compared to its Price of $1.31 per share , has below average safety , and is currently rated a Hold.

Hampton Roads (HMPR)


Bank (Southeast)


Company Information

Business: Hampton Roads Bankshares, Inc., incorporated on February 28, 2001, primarily serves as a holding company for the Bank of Hampton Roads (BOHR). The Company engages in a general community and commercial banking business, emphasizing the needs of individuals, and small to medium-sized businesses in its primary service areas, which include South Hampton Roads, Virginia, the Northeastern, Southeastern and Research Triangle regions of North Carolina, the Eastern Shore of Virginia and Maryland, and Richmond, Virginia.

Capital Appreciation

Value: Value is a measure of a stock's current worth. HMPR has a current Value of $1.37 per share. Therefore, it is fairly valued compared to its Price of $1.31 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. HMPR has an RV of 0.78, which is poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.



RS (Relative Safety): RS is an indicator of risk. HMPR has an RS rating of 0.54, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. HMPR has a Relative Timing rating of 1.02, which is fair on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. HMPR has a VST rating of 0.82, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. HMPR has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.

Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. HMPR has a Stop of $1.24 per share. This is $0.07 below below HMPR's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.

GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. HMPR has a forecasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, as shown weekly in our investment climate report.

EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. HMPR has a forecasted EPS of $-1.29 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. HMPR has a P/E of -1.02. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 40.25. P/E is computed daily using the formula: P/E = Price/EPS.

EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. HMPR has an EY of -98.47 percent. This is below the current average of 2.50% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. HMPR has a GPE rating of -6.90. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 2.57%, the operative GPE ratio is 0.07. Therefore, HMPR may be considered to be fairly valued.

Dividend Information

DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. HMPR does not pay a dividend.

DY (Dividend Yield): DY reflects dividend per share as a percent of Price. HMPR does not pay a dividend, so it does not have a Dividend Yield rating . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. HMPR does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. HMPR does not pay a dividend, so it does not have a Dividend Growth rating .

YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. HMPR does not pay a dividend, so it does not have a YSG rating which is . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for below current income and long-term growth.

Price-Volume Data

Price: HMPR closed on Thursday, March 28, 2013 at $1.31 per share.

Open: HMPR opened trading at a price of $1.32 per share on Thursday, March 28, 2013.

High: HMPR traded at a High price of $1.34 per share on Thursday, March 28, 2013.

Low: HMPR traded at a Low price of $1.31 per share on Thursday, March 28, 2013.

Close: HMPR closed on Thursday, March 28, 2013 at $1.31 per share. (Close is also called Price in the VectorVest system)

Range: Range reflects the difference between the High and Low prices for the day. HMPR traded with a range of $0.03 per share on Thursday, March 28, 2013.

$ Change: HMPR up 0.02 from the prior day's closing Price.

%PRC: HMPR's Price changed 1.55% from the prior day's closing price.

Volume: HMPR traded 82,684 shares on Thursday, March 28, 2013.

AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. HMPR has an AvgVol of 144,732 shares traded per day.

%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100. HMPR had a %Vol of -42.87% on Thursday, March 28, 2013

CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. HMPR has a CI rating of 0.40, which is very poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.

Sales / Market Capitalization Information

Sales: HMPR has annual sales of 82,000,000

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. HMPR has a Sales Growth of -12.00% per year. This is very poor. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.

Sales Per Share (SPS): HMPR has annual sales of $0.48 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): HMPR has a P/S of 2.71. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: HMPR has 170,000,000 shares of stock outstanding.

Market Capitalization: HMPR has a Market Capitalization of 223,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.

Business Sector: HMPR has been assigned to the Bank Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Industry Group: HMPR has been assigned to the Bank (Southeast) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

For another stock analysis, please click here.

Please do not reply to this email. For answers to your questions, please call 1-888-658-7638, or email us at support@vectorvest.com .

Copyright 2010 by VectorVest, Inc. All Rights Reserved.
20472 Chartwell Center Drive, Cornelius NC 28031
For additional information, call 1-888-658-7638, e-mail to support@vectorvest.com ,
or visit our internet site at http://www.vectorvest.com

For international phone numbers please click here.

DISCLAIMER: VectorVest is licensed by VectorVest, Inc., and is protected by United States copyright laws and international treaty provisions. The information contained herein is for your exclusive, personal use only. You may print a single copy of any stock analysis for your exclusive use, but it is not to be reproduced for distribution without the expressed written consent of VectorVest, Inc. You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. This material is believed to be reliable, but neither VectorVest, Inc., nor any of its suppliers guarantee its accuracy or validity, nor are they responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made by VectorVest, and/or any of its suppliers do not provide, imply, or otherwise constitute a guarantee of performance.

VectorVest is comprised of reports embodying a unique system of stock analysis. All contents and recommendations are based on data and sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Users should be aware of the risks involved in stock investments. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied. VectorVest and/or its principals may purchase or sell any of the securities cited herein. VectorVest and the logostyle, geometric design are, individually and collectively, service marks owned by VectorVest, Inc. VectorVest is published daily by VectorVest, Inc. 20472 Chartwell Center Drive Cornelius, NC 28031 704-895-4095



Xenith Bankshares, Inc. NEW (XBKS) Stock Research Links

XBKS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Qingdao's Food Trade Triumph at SIAL Paris Booms

Updated Category News Views 3

Qingdao Impresses in the Global Food Arena Well, 2026 is serving up something special from Qingdao. During SIAL Paris, everyone's talking about how Qingdao’s food companies smashed expectations with 82 million yuan in intended orders. You’ve got CCPIT Qingdao pulling the strings, setting up an exhibition platform that was nothing short of top-tier. Staging a Show at...

Continue Reading
Electrolux Trends: Q3 '26 Shows Resilience Amid Challenges

Updated Category News Views 3

Electrolux's Strategic Moves In A Tough Market Electrolux's Q3 2026 paints a gritty picture—yet there's a pulse of resilience underneath the numbers. Net sales bumped up to SEK 33,919m due to a 3.5% organic growth, showing the company's ability to swim through choppy waters. But let's not brush aside the sharp rocks they’re dodging: soaring raw materials and logistics...

Continue Reading
TORL Bio's Ixo-V Drug Shows Promise in Combatting GCT

Updated Category News Views 2

A Beacon of Hope in Germ Cell Tumor Treatment There's something brewing in the oncology world that's worth a nod. TORL BioTherapeutics has rolled out some interesting preliminary data for their hopeful cancer buster, ixotatug vedotin, or Ixo-V. This study is part of a wider effort to take a swing at recurrent germ cell tumors (GCTs) with some tough results already making...

Continue Reading
Innventure Faces Chaotic Legal Storm Over DarkNX Scandal

Updated Category News Views 1

Innventure's DarkNX Project: From Boon to Bane The stock market is no stranger to seismic shifts, but Innventure, Inc.'s recent plunge is a testament to the catastrophic impact missteps can unleash. This whole DarkNX debacle feels more like a meticulous car wreck than a business evolution. Unpacking the Allegations Sitting comfortably under the NASDAQ:INV ticker,...

Continue Reading
Lowcountry Kids to Get Free Helmets at Safety Events

Updated Category News Views 1

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Continue Reading
ImmunoForge Sets Sights on BIO-Europe 2026 for New Deals

Updated Category News Views 3

Making Waves with Cutting-Edge Drug Platforms Ah, how time flies in the biotech universe. Here we are, with ImmunoForge prepping to flaunt its high-tech gear at the big show in Cologne: BIO-Europe 2026. The company's aiming to gauge attention with its flashy ELP and LMT platforms, primed and ready for strategic partnerships. ELP: Revolutionizing Drug Delivery You've got...

Continue Reading
Greenberg Traurig Eyes Accolades in Middle East Awards

Updated Category News Views 3

Greenberg Traurig Aims for Middle Eastern Legal Dominance Ah, the legal world, where firms jostle like bulls in a market for the prestige of an award—it's not just about the courtroom victories, but also about snatching the right titles at glossy ceremonies. On the docket this time: Greenberg Traurig has its sights set on several prime accolades at the Law Middle East...

Continue Reading
California Contractors Honored for Safety Commitment

Updated Category News Views 9

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

Continue Reading
Dimethylaminopropylamine Market Eyes $732M by 2035

Updated Category News Views 0

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

Continue Reading

Top 5 Most Recently Viewed Articles

RPA Market Set to Surge with Digital Transformation Support

Updated Category News Views 218

Understanding the Growth of the Robotic Process Automation Market The Robotic Process Automation (RPA) market is experiencing remarkable growth, with forecasts indicating an increase from USD 2.8 billion in 2023 to a staggering USD 38.4 billion by 2032. This impressive growth, at a compound annual growth rate (CAGR) of 33.8% from 2024 to 2032, reflects the growing...

Continue Reading
Unlocking Hidden Gems: Two Undervalued China Stocks to Buy

Updated Category News Views 246

Discovering Hidden Opportunities in China's Stock Market As the Chinese stock market experiences a renewed rally, discerning investors are on the lookout for undervalued companies with promising growth prospects. In a landscape dominated by major players like Alibaba and Tencent, two lesser-known stocks are gaining attention: Futu Holdings (NASDAQ: FUTU) and Atour...

Continue Reading
Exploring the Rise of Medical Spas: A Booming Industry

Updated Category News Views 186

Introduction to the Medical Spa Industry The medical spa industry is experiencing an exciting evolution, reflecting a shift in consumer preferences towards services that combine traditional spa ambiance with the expertise of medical professionals. With an increasing focus on aesthetic wellness and anti-aging solutions, we are witnessing an impressive market growth...

Continue Reading
Coherent Corp. Launches Chameleon Discovery LX Laser for Researchers

Updated Category News Views 189

Coherent Corp. Launches an Innovative Femtosecond Laser Coherent Corp. (NYSE: COHR), a renowned leader in the laser and photonics industry, has unveiled the Chameleon Discovery LX, an exciting new addition to its esteemed Chameleon Discovery product line. This revolutionary femtosecond laser is specifically designed for researchers engaged in nonlinear microscopy and...

Continue Reading
Neuronetics Shows Strong Revenue Growth Amid CEO Transition

Updated Category News Views 134

Neuronetics Reports Impressive Q3 2025 Results Neuronetics, Inc., a leader in neurohealth therapies, has shared substantial financial achievements for the third quarter of 2025. The company reported total revenues of $37.3 million, marking an significant adjusted pro forma growth of 11% compared to the same quarter in the previous year. This success can largely be...

Continue Reading